Author

Samer S.A. Al Hadidi

Observed name: Samer Al Hadidi

Institutions: Mayo Clinic in Arizona, Harold C. Simmons Comprehensive Cancer Center, University of Arkansas for Medical Sciences, The University of Texas Southwestern Medical Center

Observed institutions: University of Arizona, University of Michigan, Southern Arizona VA Health Care System, Mayo Clinic in Arizona, Harold C. Simmons Comprehensive Cancer Center, University of Arkansas for Medical Sciences, The University of Texas Southwestern Medical Center

ORCID: 0000-0003-4297-8042

Observed ORCID: 0000-0003-4297-8042

OpenAlex ID: A5060113059

Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline

2026 · Lisa K. Hicks, Hans J. Messersmith, et al. · Journal of Clinical Oncology · 9

Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma

2026 · Toshali Pandey, Bhavesh Mohan Lal, et al. · Blood Cancer Journal · 2

Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review

2026 · Karun Neupane, Mitch Singstock, et al. · British Journal of Haematology · 2

The post-BCMA playbook: RD118 GPRC5D CAR T cells for myeloma

2026 · Samer Al Hadidi · Blood · 1

The meta-analysis deluge: When synthesis becomes pollution

2026 · Samer Al Hadidi · European Journal of Internal Medicine

Second primary malignancy in multiple myeloma: does a prior malignancy matter?

2026 · Alissa Visram, Hsien Seow, et al. · Haematologica

Academic Oncology at a Crossroads: Rebuilding a Sustainable Career Path

2026 · Samer Al Hadidi, Aimaz Afrough, et al. · Journal of the National Comprehensive Cancer Network

Cost-Effectiveness Analysis of Curative Therapies for Early Stage Hepatocellular Carcinoma (HCC) within Milan Criteria

2017 · Felipe A. Maegawa, Samer S.A. Al Hadidi, et al. · Journal of the American College of Surgeons

Works count: 8

Citation count: 14

H-index: 2

I10-index: